PRSS-16 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human thymus-specific serine protease (PRSS16, UniProt Q9NQE7), produced in HEK293 cells. Suited for enzymatic activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-PRSS16

In stock

SKU
REC-PRSS16
$498.00

Target Overview

PRSS16 (UniProt Q9NQE7), also designated Serine Protease 16 or Thymus-Specific Serine Protease (TSSP), is a 514-amino-acid serine endopeptidase whose expression is highly restricted to the thymus. The protein localises to cytoplasmic vesicles and is proposed to participate in antigen processing pathways that support T-cell development, placing it in a functionally distinct niche among the broader trypsin-family serine proteases. This recombinant form is produced in HEK293 mammalian cells, an expression system that supports the post-translational modifications — including glycosylation — likely to be relevant to the native protein's folding and activity. The full-length coding sequence of 514 residues is the basis for this construct; researchers requiring a defined sequence span should confirm the exact expressed region in the certificate of analysis. In the laboratory, this recombinant is well-suited as a substrate for direct enzymatic characterisation: fluorogenic or chromogenic peptide-substrate cleavage assays can be used to define catalytic parameters, and the preparation provides a defined antigen for inhibitor IC₅₀ determinations. Because PRSS16 expression is restricted to thymic epithelium, the recombinant also serves as a highly specific positive-control antigen in antibody-based assays. Researchers performing Western blot or immunohistochemistry validation of anti-PRSS16 antibodies can pair this recombinant with the matched Triple Point Biologics antibody (SKU: RP-PRSS16), available separately on this site, to establish signal specificity and titration ranges. The HEK293-expressed material is also appropriate for biophysical binding studies, including SPR and BLI, where a mammalian-folded protein is preferred over bacterially derived alternatives.

Background

PRSS16 encodes a serine protease whose transcript and protein expression is among the most thymus-restricted in the human genome. Early characterisation placed the protein in cytoplasmic vesicles of thymic epithelial cells, and its proposed role centres on processing peptide antigens presented to developing T cells — a function analogous to, yet mechanistically distinct from, the well-characterised cathepsin family of endolysosomal proteases. This restricted expression pattern has made PRSS16 a useful marker in thymic tissue research and has drawn interest in contexts where thymic biology intersects with immune system development and autoimmunity. In genetic association studies, PRSS16 has emerged as a locus of interest beyond the thymus. Cabrera-Serrano AJ et al. (2026) identified PRSS16 among genetic risk factors examined in a meta-analysis of rheumatoid arthritis and radiographic axial spondyloarthritis across three large European populations, reflecting the broader interest in how thymus-expressed genes shape adaptive immune repertoire and autoimmune susceptibility (PMID: 42112340). Separately, differential methylation at the PRSS16 locus has been detected in epigenomic profiling studies of vascular pathology, including work on ascending aortic aneurysm with comorbid atherosclerosis (PMID: 39707852), suggesting the gene's regulatory landscape may carry information relevant to inflammatory and cardiovascular research contexts. In tumour biology, the thymic origin of PRSS16 makes it relevant to thymoma and thymic carcinoma research. Li H et al. (2023) assessed the clinicopathological significance of thymic epithelial marker expression — including serine proteases characteristic of thymic epithelium — in thymoma and thymic carcinoma specimens, underscoring the utility of recombinant thymic proteins as reference standards and assay controls in this research area (PMID: 36797681). Studies of thymic involution and regeneration — including work examining pregnancy-induced changes in thymic architecture (PMID: 37802854) — similarly rely on well-characterised thymic markers as molecular reference points. Recombinant PRSS16 provides a defined, mammalian-expressed reagent for these contexts: as an enzymatic substrate in protease activity panels, as a calibration standard in quantitative immunoassays, or as an antigen for generating and validating research antibodies directed at this unusual serine protease. All disease-context applications of this reagent are for basic and translational research use only.

Applications

  • Fluorogenic peptide-substrate cleavage assay to determine PRSS16 serine protease kinetic parameters (Km, kcat)
  • Inhibitor IC50 determination using small-molecule serine protease inhibitor libraries
  • Positive-control antigen for Western blot validation of anti-PRSS16 antibodies, paired with RP-PRSS16
  • Immunohistochemistry titration standard for anti-PRSS16 antibody optimisation in thymic tissue sections
  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) binding studies with candidate interaction partners
  • ELISA capture/detection antigen for quantitative immunoassay development
  • Recombinant standard for mass spectrometry-based proteomic method development and peptide reference matching

References

  1. Cabrera-Serrano AJ et al. Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization. Front Immunol. 2026. doi:10.3389/fimmu.2026.1637735. PMID: 42112340.
  2. Goncharova IA et al. [DNA Methylation Profiling in Aneurysm and Comorbid Atherosclerosis of the Ascending Aorta]. Mol Biol (Mosk). 2024. doi:10.31857/S0026898424030069. PMID: 39707852.
  3. Shu YY et al. [Mechanism of pregnancy-induced thymus involution and regeneration and medication rules of postpartum prescriptions]. Zhongguo Zhong Yao Za Zhi. 2023. doi:10.19540/j.cnki.cjcmm.20230322.701. PMID: 37802854.
  4. Li H et al. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma. BMC Cancer. 2023. doi:10.1186/s12885-023-10619-6. PMID: 36797681.
  5. Li G et al. Comprehensive analysis of a TPX2-related TRHDE-AS1/PKIA ceRNA network involving prognostic signatures in Hepatitis B virus-infected hepatocellular carcinoma. Front Cell Infect Microbiol. 2022. doi:10.3389/fcimb.2022.1025900. PMID: 36204642.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted (most); pancreas + serum (digestive proteases)

Frequently Asked Questions

What molecular weight should I expect for recombinant PRSS-16 on SDS-PAGE or Western blot?

The unmodified 514-amino-acid sequence predicts a molecular weight of approximately 57 kDa. However, because REC-PRSS16 is expressed in HEK293 cells, N-linked glycosylation is expected to shift the apparent MW on SDS-PAGE to roughly 60–70 kDa, depending on gel conditions and glycan heterogeneity. Under reducing conditions, a single predominant band in this range confirms intact, properly folded protein. If you observe a doublet, this likely reflects differential glycosylation rather than contamination — purity is confirmed >90% by SDS-PAGE on every lot.

Is recombinant PRSS-16 full-length or a processed/truncated form, and does it contain the signal peptide?

The construct is based on the full 514-residue coding sequence of PRSS16 (UniProt Q9NQE7). Like other trypsin-family serine proteases, PRSS16 is likely produced as a zymogen requiring proteolytic activation; the recombinant is expressed in HEK293 cells and supplied in active form, but researchers investigating zymogen processing or propeptide cleavage should verify the exact expressed boundaries in the certificate of analysis for their specific lot. Signal peptide removal by the HEK293 secretory machinery is anticipated.

What substrates does PRSS-16 cleave and which fluorogenic peptide substrates work for activity assays?

PRSS16 is a serine endopeptidase of the trypsin family, so it preferentially cleaves after basic residues (Arg, Lys). Fluorogenic substrates such as Boc-Gln-Ala-Arg-AMC or Z-Arg-Arg-AMC are reasonable starting points for activity assays. Measure fluorescence at Ex/Em 380/460 nm. Because PRSS16's precise in-vivo cleavage specificity in antigen-processing pathways is not fully resolved, we recommend running a substrate panel alongside a trypsin control to establish baseline hydrolysis rates and validate that your preparation is active prior to inhibitor studies.

What buffer conditions and pH are optimal for PRSS-16 serine protease activity assays?

REC-PRSS16 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — conditions compatible with direct dilution into most activity assay buffers. For enzymatic assays, a working buffer of 50 mM Tris-HCl or HEPES pH 7.5–8.0, 100–150 mM NaCl, 0.01% Triton X-100 (to reduce surface adsorption) is a practical starting point. Serine proteases in this family are typically inhibited by PMSF or AEBSF — avoid these in assay buffers. Pre-warm enzyme to 25°C or 37°C for 10 minutes before initiating reactions.

What starting concentration of recombinant PRSS-16 should I use for an IC50 inhibitor assay?

For IC50 determinations, a typical starting point is 5–20 nM REC-PRSS16 in the assay well, depending on your substrate concentration and the Km of the substrate chosen. Titrate enzyme concentration first to confirm linear substrate hydrolysis over the assay time window (30–60 min is typical). Keep enzyme below 10% substrate conversion at the chosen time point to maintain initial-rate conditions. Dilute from the stock in assay buffer supplemented with 0.1% BSA to minimize adsorption losses, particularly at sub-nanomolar enzyme concentrations.

Can I use REC-PRSS16 as a positive control for Western blot with the matched PRSS-16 antibody (RP-PRSS16)?

Yes — REC-PRSS16 and the matched rabbit polyclonal RP-PRSS16 (see /anti-prss-16-rabbit-polyclonal-antibody) are produced and validated together in the same lab, making this the most reliable positive-control pairing available. The antibody is validated for Western blot and is guaranteed compatible with this recombinant. Load 10–50 ng of REC-PRSS16 per lane under reducing conditions; expect a band at ~60–70 kDa. This loading range typically yields a clean, strong signal without saturation, allowing you to co-run it alongside cell lysate lanes for direct band-size confirmation.

How much recombinant PRSS-16 should I load as a Western blot positive control, and what band should I see?

Load 20–50 ng of REC-PRSS16 per lane on a 10–12% SDS-PAGE gel under reducing conditions. Paired with RP-PRSS16 (SKU: RP-PRSS16), expect a primary band at approximately 60–70 kDa, reflecting the glycosylated HEK293-expressed form. This range consistently produces a detectable band without overwhelming nearby lanes in multiplexed blots. If you are optimizing RP-PRSS16 antibody dilution simultaneously, running a 2-fold dilution series of the recombinant (10–100 ng) alongside your lysate samples is an efficient way to establish both antibody sensitivity and linearity in a single experiment.

How should I store and handle recombinant PRSS-16 to maintain activity, and what is the shelf life?

REC-PRSS16 is shipped on dry ice and should be stored at -20°C immediately upon receipt in the single-use aliquots provided. Repeated freeze-thaw cycles measurably reduce serine protease activity — aliquot further if your working volume is smaller than the unit size. In storage buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol), the protein is stable for at least 12 months at -20°C when handled correctly. Once thawed, keep on ice and use within the same working session. Adding 0.1% BSA as a carrier can help maintain activity during prolonged dilution steps at low protein concentrations.

Validation imagery coming soon

Western blot validation figures for REC-PRSS16 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →